Navigation Links
Cellectis Unveils Its New Corporate Website
Date:9/22/2010

PARIS, Sept. 22 /PRNewswire/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, has announced the launch of its new corporate website. Visitors to this new website are ensured an enhanced usability and information sharing, including more streamlined access to technology and product-related information.

The new Cellectis website focuses on three central themes:

  • Research and Technologies
  • Business Development
  • Investor relations.

In addition to these key areas, the website offers new features and fresh content including:

  • Several specific RSS feeds which enables users to monitor the Company's business in real time, choosing only the subjects they are interested in
  • Social media links (Facebook and Twitter)
  • Downloadable documents that explains Cellectis' technology.

Founded in 1999 by Andre Choulika, PhD and David Sourdive, PhD, Cellectis today has a workforce of over 120 people and 4 subsidiaries, including one located in the U.S. Due to a steady increase in business over the past several months, Cellectis decided to offer its web visitors a showcase that presents the Company' businesses, products and achievements in the most comprehensive manner possible.

Other highlights include the following:

  • A glossary, containing all definitions required to keep up-to-date with Cellectis' activities
  • A graphic library available to qualified journalists, which includes photographs of Cellectis' products and facilities, classified by theme. Journalists need only to register to access and download the files.

The new website can be accessed at: www.cellectis.com.

About Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools – meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending. Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over euro 70 million in funding since inception.

More information at www.cellectis.com

Follow our news on Twitter: twitter.com/cellectis.

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.


'/>"/>
SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Taconics Litigation Contesting License Termination By Cellectis Is Dismissed
2. Cellectis bioresearch Establishes The Genome Customization Award (TGCA)
3. Cellectis to Present at the FASEB Summer Research Conference on Genome Engineering
4. Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
5. Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology
6. iCyt Unveils New Flow Cytometry Products in Collaboration with Sony at CYTO2010
7. ClearTrial Unveils New Product Release at Partnerships in Clinical Trials Conference 2010
8. Johnson & Johnson Consumer Companies, Inc., Unveils CYTOMIMIC(TM) Technology at 68th Annual Meeting of the American Academy of Dermatology
9. Stem Cell Assurance Unveils Physician Network Offering Regenerative Cell Cosmetic and Reconstructive Applications
10. Brooks Instrument Unveils New Web site
11. North Carolina-based Cnanoz Unveils NanoPure(TM) to Government Leaders in Hyderabad, India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... RPS ... clinical study that demonstrates the accuracy of the FebriDx® test, a commercially-ready, ... acute bacterial and viral respiratory tract infections by testing the body’s immune ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
Breaking Biology Technology:
(Date:6/30/2017)... Va. , June 30, 2017 ... leading developer and supplier of face and eye ... ATA Featured Product provider program. ... an innovative way to monitor a driver,s attentiveness ... greatly from being able to detect fatigue and ...
(Date:5/16/2017)... 16, 2017   Bridge Patient Portal , ... MD EMR Systems , an electronic medical ... GE, have established a partnership to build an ... the GE Centricity™ products, including Centricity Practice Solution ... These new integrations will allow healthcare delivery ...
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):